Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model

• Published in: Journal of biomedical materials research 2003-09, Vol.66A (4), p.747-754
• Main Authors: Matsuo, Toshihiro, Sugita, Takashi, Kubo, Tadahiko, Yasunaga, Yuji, Ochi, Mitsuo, Murakami, Teruo
• Format: Article
• Language: English
• Subjects: active targeting; Animals; Biological and medical sciences; Bone and Bones - abnormalities; Bone Development - drug effects; bone formation; bone morphogenetic protein; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins - administration & dosage; Bone Morphogenetic Proteins - pharmacology; Disease Models, Animal; Drug Carriers; Humans; injectable carrier; Liposomes; magnetic liposomes; Magnetics; Male; Medical sciences; Microscopy, Electron; Rats; Rats, Sprague-Dawley; Recombinant Proteins - administration & dosage; Recombinant Proteins - pharmacology; Transforming Growth Factor beta
• ISSN: 1549-3296; 0021-9304; 1552-4965; 1097-4636
• DOI: 10.1002/jbm.a.10002

Small‐sized magnetic liposomes with incorporated recombinant human bone morphogenetic protein‐2 (rhBMP‐2) were prepared, and the efficiency for bone formation after topical injection was evaluated in a rat bone‐defect model. A critical‐sized segmental bone defect was created in the mid‐part of the femoral shaft, and a permanent magnet was attached. Topical injection onto the defects was performed with different liposomal preparations (nonmagnetic and magnetic liposomes) using different treatment modalities (different doses and different treatment timing of rhBMP‐2). Weekly evaluations were made radiographically and microcomputed tomographically, histologically, and/or by mechanical testing at 9 weeks after surgery. A single topical application of magnetic liposomes with an appropriate amount of rhBMP‐2 (≈3 μg) incorporated under magnetic induction immediately after surgery was effective for new bone formation. The combined treatment of topical magnetic rhBMP‐2 liposomes and magnetic implantation at the injury site was effective for the treatment of bone defects. This injectable carrier for BMP is expected to have many advantages over solid carriers because it can be prepared easily and can be less invasively applied to the injured site at any time after surgery. © 2003 Wiley Periodicals, Inc. J Biomed Mater Res 66A: 747–754, 2003